No substantial TKI effects were observed in KIT-independent GIST cell lines GIST48B and GIST226 (Table 1), which underscores that TKI-activity is typically mediated by blocking KIT signalling in imatinib-resistant GIST. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.